The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Investment with representation on the Board of Directors and technical know-how
The patient, who was previously diagnosed with osteoarthritis, was prescribed hip replacement surgery as the best and most effective solution for his condition
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
